• Ipsen in talks with NICE over Cabometyx rejection pharmatimes
    April 21, 2017
    Ipsen says discussions with the National Institute for Health and Care Excellence are ongoing following a second rejection of Cabometyx for advanced renal cell carcinoma (RCC).
PharmaSources Customer Service